

NEKTAR THERAPEUTICS  
Form 8-K  
July 31, 2003

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## FORM 8-K

**Current Report Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **July 30, 2003**

### **Nektar Therapeutics**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of incorporation)

**000-23556**  
(Commission File No.)

**94-3134940**  
(IRS Employer Identification No.)

**150 Industrial Road**  
**San Carlos, CA 94070**  
(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: **(650) 631-3100**

---

**Item 5. Other Events**

On July 30, 2003, Nektar Therapeutics announced that the initial purchasers have exercised their option granted pursuant to a purchase agreement dated June 25, 2003 with respect to Nektar's 3% convertible subordinated notes due 2010 to purchase an additional \$10 million in aggregate principal amount of such notes. The closing of the additional purchase pursuant to the option increases the aggregate principal amount of 3% convertible subordinated notes sold to \$110 million.

Nektar's press release, dated July 30, 2003, titled "Nektar Announces Exercise of Option to Purchase \$10 Million of Convertible Subordinated Notes" is attached hereto as Exhibit 99.1.

**Item 7. Financial Statements and Exhibits**

**(c) Exhibits**

| Exhibit Number | Description                                                                                                                                |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| 99.1           | Press Release titled "Nektar Announces Exercise of Option to Purchase \$10 Million of Convertible Subordinated Notes" dated July 30, 2003. |

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**NEKTAR THERAPEUTICS**

Dated: July 30, 2003

By: /s/ Ajay Bansal  
Ajay Bansal

*Chief Financial Officer and Vice  
President, Finance and Administration*